ToolGen, a company specializing in gene editing, announced on the 25th that it has signed a business agreement with enParticle, a company specializing in microfluidics-based particle manufacturing, to develop an LNP production process for the delivery of genetic scissors.
For mutual cooperation, the two companies reviewed the possibility of technology convergence from last year and started basic joint research on the possibility of combining the two technologies. Through this business agreement, the scope of joint research will be expanded.
enParticle’s microfluidic particle manufacturing technology can continuously produce uniformly sized LNPs and dramatically reduces the cost and time required. Through this cooperation, the company plans to take a step forward in commercialization by efficiently producing LNPs equipped with ToolGen’s genetic scissors technology.
Koh Jung-sang, CEO of enParticle, said, “We expect that this cooperation will bring us one step closer to commercialization of gene therapy production using enParticle’s microfluidic engineering technology.”
Toolgen CEO Kim Young-ho said, “In order to increase the competitiveness of CRISPR-based therapeutics, we are increasing competitiveness by combining various technologies such as mRNA and LNP.” I look forward to it,” he said.
Source: Medigate News (https://www.medigatenews.com)
